Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis

World Journal of Surgical Oncology

Research

Buwen Zhang¹  Tao Xu² 

[1] Department of Oncology, Changxing People’s Hospital, 313199, Huzhou, Zhejiang, China;Department of Urology, Changxing People’s Hospital, 313199, Huzhou, Zhejiang, China;

关键词: Systemic immune-inflammation index;    Prostate cancer;    Meta-analysis;    Prognostic factors;    Clinical use;   

DOI  :  10.1186/s12957-022-02878-7

 received in 2022-09-18, accepted in 2022-12-09,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundThe SII (systemic immune-inflammation index) has been extensively reported to have a prognostic value in prostate cancer (PCa), despite the unconformable results. The purpose of this meta-analysis is to quantify the effect of pretreatment SII on survival outcomes in patients with PCa.MethodsThe following databases were searched: Web of Science, Cochrane Library, PubMed, Embase, and China National Knowledge Infrastructure (CNKI). For exploration of the SII’s correlations with the overall survival (OS) and the progression-free survival/biochemical recurrence-free survival (PFS/bRFS) in PCa, the pooled hazard ratios (HRs) were assessed within 95% confidence intervals (CIs).ResultsThe present meta-analysis covered 10 studies with 8133 patients. Among the PCa population, a high SII was linked significantly to poor OS (HR = 2.63, 95% CI = 1.87–3.70, p < 0.001), and worse PFS/bRFS (HR = 2.49, 95% CI = 1.30–4.77, p = 0.006). However, a high SII was not linked significantly to T stage (OR = 1.69, 95% CI = 0.86–3.33, p = 0.128), the metastasis to lymph node (OR = 1.69, 95% CI = 0.69–4.16, p = 0.251), age (OR = 1.41, 95% CI = 0.88–2.23, p = 0.150), or the Gleason score (OR = 1.32, 95% CI = 0.88–1.96, p = 0.178).ConclusionsFor the PCa sufferers, the SII might be a promising prognostic biomarker, which is applicable to the high-risk subgroup identification, and provide personalized therapeutic strategies.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq507.gif

Fig. 27

41116_2022_35_Article_IEq503.gif

41116_2022_35_Article_IEq501.gif

41116_2022_35_Article_IEq497.gif

41116_2022_35_Article_IEq493.gif

Fig. 24

41116_2022_35_Article_IEq485.gif